Page last checked 2026-08-12

Research compound · not FDA-approved

Hexarelin

Hexarelin is a peptide six amino acids long, built in the early 1990s to trigger a growth-hormone pulse.

What matters first

Why people look it up: Sellers pitch it as the hardest-hitting of the growth-hormone peptides, for muscle and recovery.
What the evidence shows: The pulse gets smaller as the doses repeat. On the only long course on record it had roughly halved by week 16, and came back only once the drug stopped. No trial turned that into a schedule, and none measured muscle.
Dose status: Hexarelin is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Evidence snapshot

Foreign approval or limited human data

The fastest way to see what kind of evidence this page is built on.

Regulation: Not FDA-approvedNo US prescribing label
Dose source: Human study3 reported dose rows
Safety evidence: 6 listed safety findingsCommon and serious effects shown apart
Sources: 5 cited sourcesMedical review complete · 2026-08-12

Open the shareable evidence image

Hexarelin at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how good the evidence is · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12open the primary sources

What is known about Hexarelin

Hexarelin is a six-residue synthetic secretagogue, built in the early 1990s from the growth-hormone-releasing peptide series. It acts at the ghrelin receptor, and it also binds the scavenger receptor CD36 in heart tissue. Human pharmacology studies showed it provokes a pituitary growth-hormone pulse. The same studies showed something more awkward: repeated doses produce a smaller pulse. No trial turned that fading into a schedule, and none ever settled a dose that works.

Hexarelin research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic	Value
Strongest source	limited human data
FDA approval	Not FDA-approved
Studied dosing	1.5 mcg per kilogram of body weight, twice daily for 16 weeks in healthy elderly volunteers; the growth-hormone response fell from 19.1 to 10.5 mcg/L·h by week 16 and returned to 19.4 four weeks after stopping — from clinical trials
Studied dosing	1.5 mcg per kilogram of body weight, two or three times in a day in six normal young men; both schedules raised 24-hour growth hormone by the same amount, and neither moved IGF-I — from clinical trials
Studied dosing	0.125–1 mcg per kilogram of body weight, as a single dose in healthy adult men; the growth-hormone curve flattened at 1.0 mcg/kg, with half the maximum response at 0.48 mcg/kg — from clinical trials
What people report using	100–200 mcg once or twice a day, continued for weeks at a time; the one study that dosed anyone for 16 weeks watched the growth-hormone response fall by nearly half over that period — no trial has tested this quantity
Typical vials	2 mg · 5 mg

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

The row headed “what people report using” is not evidence. No trial produced that quantity. It is printed because it is what circulates, and because it is better read here, beside what the studies actually did, than on a page that is selling the vial. It describes a practice. It is not a starting point.

What the evidence for Hexarelin is

People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.

limited human data

What it establishes: It shows that people have received it and that some human information exists.
What it does not establish: It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.

Where Hexarelin is in clinical trials

No trial of this compound is registered on ClinicalTrials.gov.

That is worth sitting with. Nobody has registered a study to find out whether Hexarelin works in people, so no result is coming and no date is worth waiting for. Sellers are not waiting for that work either.

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-08-23

Every compound we track, and what stage each one has reached →

Regulatory status

No sponsor holds an approval for hexarelin anywhere, and no trial program stands behind it.

In December 2025 FDA named the acetate salt in a warning letter to an ingredient broker. The letter listed the salt among substances FDA treats as off-limits for human drug compounding. So FDA has looked at the route by which this reaches pharmacies, rather than leaving it alone.

Anti-doping rules separately bar secretagogues as a class at all times.

Full regulatory tracker →

Where to go next on Hexarelin

The schedule, the side effects and the mixing math each have their own page.

Which hexarelin reactions warrant medical attention

No boxed warning applies to hexarelin, which reflects the review it has not had.

The hexarelin trial dosing program, arm by arm

See what each hexarelin trial group received; this is not an approved schedule.

Doses per 2 mg hexarelin vial, on the calculator

The nearest syringe line to the target, and the rounding error it introduces for hexarelin.

Reconstituting hexarelin at 2 mg, step by step

The 2 mg hexarelin table itself, not a general rule applied to an unrelated vial size.

What each water volume does to the 5 mg hexarelin vial

Every option for the 5 mg hexarelin vial, with an example draw on a U-100 barrel.

The muscle growth page hexarelin appears on

2 of the 6 muscle growth rows rest on reported use and nothing more, with hexarelin as context

Mixing math for any vial, not just hexarelin

One calculator for every vial on this site, with hexarelin as one example

Where the hexarelin program has actually got to

A registration is a plan and never gets reported as a result, with hexarelin as context

Primary regulatory documents, including hexarelin

Every URL was fetched and live on its retrieval date, hexarelin or otherwise.

Where hexarelin sits among the source-checked pages

See the strongest source available for every compound, with hexarelin as context

Safety notes

The growth-hormone response reported in human studies got weaker as the dose repeated. By week 16 of the only long course on record it had roughly halved, and it came back only after the drug stopped
Every published human quantity is per kilogram of body weight, so none of them converts to a vial without a weight
The intravenous dose curve flattens at 1 mcg/kg, and the same study found cortisol rising from 0.5 mcg/kg upward. Going higher buys hormones nobody was aiming for, not more growth hormone
Binds CD36 in cardiac tissue, a target unrelated to the pituitary effect people seek it for
Prohibited at all times under the World Anti-Doping Agency secretagogue class
No approval anywhere and no active investigational program

Questions about Hexarelin

Is Hexarelin FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Hexarelin taken?

Trials study it both by injection under the skin and by drip or injection into a vein. The table above keeps each route and schedule separate.

How does Hexarelin differ from the other compounds in this class?

Hexarelin has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.

What is not known about Hexarelin?

It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Is there a Hexarelin dosing schedule on this site?

Not a schedule — there is no approved schedule to publish here. What you get instead is the trial dosing program: the doses each arm received and how the protocol worked up to them. The studied range was 1.5–1.5 mcg per kilogram of body weight, twice daily for 16 weeks in healthy elderly volunteers; the growth-hormone response fell from 19.1 to 10.5 mcg/L·h by week 16 and returned to 19.4 four weeks after stopping. See what the trials tested.

5primary sources, each with the day we read it — open the documents used on this page